US AI
Beyond's analysis on US AI
- — Chinese AI firms are rapidly closing the performance gap with leading US models, signaling a shift in global AI competitiveness
- — US lifts export ban on Anthropic’s top AI models, restoring access to Claude Fable 5 and Mythos 5
- — US block on Anthropic AI software heightens German digital sector's reliance on US technology
Recent news mentioning US AI
- — Timekettle Unveils W4 Plus AI Interpreter Earbuds at IFA 2026, Bringing AI-Powered Translation to Conversations, Calls and Digital Content
- — Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?
- — Tempus AI Director Nadja West Sells 3,000 Shares for $207,000
- — Bayesian Health's FDA-Cleared Continuous AI Sepsis Monitor Approved for Medicare New Technology Add-on Payment (NTAP)
- — Tempus AI shares rise 2.7% following analyst actions
- — Think unveils Think Fabric™, a new approach to bare-metal, heterogeneous AI compute built for the age of efficiency
- — Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
- — Unanimous AI Releases (Co)agents -- Proactive AI Coworkers that Join Group Discussions and Significantly Amplify Team Intelligence
- — La CFDT défend la taxation de l’héritage «dès le premier euro» et la mise à contribution des retraités les plus aisés
- — Why Tempus AI Skyrocketed This Week
- — A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know
- — Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade